Weight loss drug Orexigen Therapeutics’ Contrave gets rejected by FDA
Linkedin

Weight loss drug Orexigen Therapeutics’ Contrave gets rejected by FDA

New York City : NY : USA | Feb 01, 2011 at 11:36 AM PST
XX XX
Views: Pending
 

According to media sources, the weight loss drug, Orexigen, has been rejected by the Food and Drug Administration. FDA announced today that they have conducted a detailed study on the effects of Contrave on the heart.

The authorities have said that Contrave, which is a mixture of the antidepressant bupropion and the anti addiction drug naltrexone, works by boosting metabolism while curbing appetite and cravings.

The weight loss drug, Orexigen Therapeutics’ Contrave, got a 13 to 7 majority voting approval in December and it was endorsed by an FDA advisory committee. The agency later became concerned about Orexigen Therapeutics’ Contrave’s safety.

According to the administration, the pilot clinical testing they conducted for Orexigen Therapeutics’ Contrave consisted of 5000 participants out of which nearly 35% lost at least 5% of their body weight; however, they also experienced a slight increase in their blood pressures.

Claire87 is based in San Francisco, California, United States of America, and is a Reporter for Allvoices.
Report Credibility
 
  • Clear
  • Share:
  • Share
  • Clear
  • Clear
  • Clear
  • Clear
 
 
 
Advertisement
 

News Stories

 
  • FDA declines to approve Oregixen diet drug

      AP Online
    Orexigen Therapeutics Inc. says U.S. health officials have declined to approve the experimental weight loss pill Contrave and want the company to conduct an additional study. The Food and Drug Administration request suggests the agency...
  • FDA rejects another diet pill

      Washington Post's The Checkup
    The Food and Drug Administration notified Orexigen Therapeutics of San Diego that it would not authorize the sale of the drug Contrave, according to a statement released Tuesday by the company. The FDA "noted concern about the cardiovascular safety...
  • FDA declines to approve Orexigen diet drug

      The Daily Herald
    Orexigen Therapeutics Inc. said Tuesday that U.S. health officials declined to approve the experimental weight loss pill Contrave and want the company to conduct an additional study to address potential heart safety concerns. The announcement sent...
  • FDA Rejects New Diet Pill Over Heart Concerns- Signs of a Heart Attack

    U.S. health regulators rejected Orexigen Therapeutics Inc's weight-loss drug and requested a clinical trial to resolve heart safety concerns, dealing a stunning blow to what stood to be the first new diet pill in a decade. Orexigen shares plunged 71...
  • FDA Rejects New Diet Pill Over Heart Safety Concerns

      Fox News
    U.S. health regulators rejected Orexigen Therapeutics Inc's weight-loss drug and requested a clinical trial to resolve heart safety concerns, dealing a stunning blow to what stood to be the first new diet pill in a decade. Orexigen shares plunged 71...
  • FDA rejects another obesity drug

      paging dr. gupta
    In the last 12 months, the FDA has nixed three new weight-loss drugs, lorcaserin because of possible links to cancer, Qnexa and now Contrave because of possible heart problems. In December, an advisory committee for the FDA first voted  in favor of...

Blogs

 >

More From Allvoices

Report Your News Got a similar story?
Add it to the network!

Or add related content to this report



Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Allvoices, Inc. 2008-2014. All rights reserved. Powered by PulsePoint.